Traitement par iode-131 des hyperthyroïdies et risque de cancer: mythe ou réalité

Translated title of the contribution: Discussion on radioactive iodine treatment of hyperthyroidism and the risk of induced cancer

E. Hindié, K. B. Ain, S. Zerdoud, A. M. Avram

Research output: Contribution to journalShort surveypeer-review

Abstract

Iodine-131 (131I, radioiodine) has been used for over eight decades for the treatment of Graves’ disease, either as initial therapy or following failure of thionamides, as well as for the treatment of autonomous thyroid nodules. 131I treatment is simple to administer, effective, and relatively inexpensive. Recently, there has been some turmoil after a study published in JAMA Internal Medicine reported an increased risk of cancer from 131I treatment. The impact was of short duration however, as the paper received severe criticisms from many nuclear medicine physicians as well as from endocrinologists. Here we explain why that paper's conclusions are doubtful. We also review the major data on the topic of 131I therapy of hyperthyroidism and the risk of cancer.

Translated title of the contributionDiscussion on radioactive iodine treatment of hyperthyroidism and the risk of induced cancer
Original languageFrench
Pages (from-to)287-289
Number of pages3
JournalMedecine Nucleaire
Volume44
Issue number4
DOIs
StatePublished - Oct 2020

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Masson SAS

Keywords

  • Cancer
  • Hyperthyroidism
  • I
  • Radioactive iodine
  • Radioiodine therapy
  • Secondary cancer

ASJC Scopus subject areas

  • Biophysics
  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Discussion on radioactive iodine treatment of hyperthyroidism and the risk of induced cancer: mythe ou réalité'. Together they form a unique fingerprint.

Cite this